Named on one round in the feed.
Since 2026-11-02
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Specific Biologics A biotechnology company pioneering a new generation of precision gene-editing therapies for serious genetic diseases | Series A Verified against 3 of 4 sources | $35M | 2026-11-02 | [ PART ] |
No sector on record.